8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Nov 20, 2025·SEC
Edgewise Therapeutics, Inc.(EWTX)Earnings, Financials & Key Ratios
EWTX•NASDAQ
Price updated Jun 19, 2026
AboutEdgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Show more
- Revenue$0
- EBITDA-$189M-20.8%
- Net Income-$168M-25.4%
- EPS (Diluted)-1.63-12.4%
- ROE-34.19%+0.6%
EWTX Key Insights
Edgewise Therapeutics, Inc. (EWTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 90 (top 10%)
✗Weaknesses
- ✗Profits declining 58.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 11.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EWTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EWTX Price & Volume
Edgewise Therapeutics, Inc. (EWTX) stock price & volume — 10-year historical chart
Loading chart...
EWTX Growth Metrics
Edgewise Therapeutics, Inc. (EWTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-20.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.1%
Return on Capital
10 Years-31.83%
5 Years-31.51%
3 Years-37.7%
Last Year-38.74%
EWTX Recent Earnings
Edgewise Therapeutics, Inc. (EWTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.46+8.0%
$0.50
Rev
—
—
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.47-9.3%
$0.43
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.39+2.5%
$0.40
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.34+19.0%
$0.42
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.46vs $0.50+8.0% | — |
| Q1 2026 | Feb 26, 2026 | $0.47vs $0.43-9.3% | — |
| Q4 2025 | Nov 6, 2025 | $0.39vs $0.40+2.5% | — |
| Q3 2025 | Aug 7, 2025 | $0.34vs $0.42+19.0% | — |
Based on last 12 quarters of dataView full earnings history →
EWTX Peer Comparison
Edgewise Therapeutics, Inc. (EWTX) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 MGTX | 1.05B | 11.32 | -7.97 | 144.57% | -151.12% | -368.19% | ||
 MDGL | 11.66B | 505.75 | -39.36 | 432.05% | -27.32% | -50.15% | 0.59 |
Compare EWTX vs Peers
Edgewise Therapeutics, Inc. (EWTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EWTX Income Statement
Edgewise Therapeutics, Inc. (EWTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 123K | 185K | 0 | 0 | 0 | 0 | 2.27M | 590K |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | -123K▲ 0% | -185K▼ 50.4% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -2.27M▲ 0% | -590K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | -50.41% | 100% | - | - | - | - | - |
Operating Expenses | 9.92M | 17.01M | 43.22M | 71.66M | 114.36M | 158.83M | 189.14M | 198.97M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 1.3M | 2.21M | 11.03M | 17.63M | 23.45M | 31.87M | 40.02M | 42.28M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 8.62M | 14.8M | 32.19M | 54.03M | 90.91M | 126.97M | 151.39M | 157.28M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -2.27M | -590K |
Operating Income | -9.92M▲ 0% | -17.19M▼ 73.2% | -43.22M▼ 151.4% | -71.66M▼ 65.8% | -114.36M▼ 59.6% | -158.83M▼ 38.9% | -191.41M▼ 20.5% | -199.56M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -73.24% | -151.37% | -65.82% | -59.59% | -38.89% | -20.51% | - |
EBITDA | -9.8M | -17.01M | -42.94M | -71.12M | -112.63M | -156.54M | -189.14M | -199.53M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -73.52% | -152.5% | -65.61% | -58.36% | -38.99% | -20.82% | -18.96% |
D&A (Non-Cash Add-back) | 123K | 185K | 272K | 538K | 1.73M | 2.29M | 2.27M | 36K |
EBIT | -9.92M | -17.19M | -43.22M | -71.66M | -114.36M | -158.83M | -167.79M | -187.61M |
Net Interest Income | 219K | 69K | 402K | -1.35M | 14.19M | 25.02M | 23.61M | 23.55M |
Interest Income | 219K | 69K | 402K | 2.66M | 14.19M | 25.02M | 23.61M | 23.55M |
Interest Expense | 0 | 0 | 0 | 4.02M | 0 | 0 | 0 | 0 |
Other Income/Expense | 219K | 69K | 402K | 4.02M | 14.19M | 25.02M | 23.61M | 23.55M |
Pretax Income | -9.71M▲ 0% | -17.12M▼ 76.4% | -42.81M▼ 150.0% | -67.64M▼ 58.0% | -100.16M▼ 48.1% | -133.81M▼ 33.6% | -167.79M▼ 25.4% | -176.01M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -9.49M▲ 0% | -17.05M▼ 79.8% | -42.81M▼ 151.0% | -67.64M▼ 58.0% | -100.16M▼ 48.1% | -133.81M▼ 33.6% | -167.79M▼ 25.4% | -176.01M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -79.78% | -151.04% | -57.99% | -48.08% | -33.6% | -25.4% | -20.48% |
Net Income (Continuing) | -9.71M | -17.12M | -42.81M | -67.64M | -100.16M | -133.81M | -167.79M | -176.01M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.19▲ 0% | -0.35▼ 84.2% | -0.86▼ 145.7% | -1.26▼ 46.5% | -1.57▼ 24.6% | -1.45▲ 7.6% | -1.63▼ 12.4% | -1.64▲ 0% |
EPS Growth % | - | -84.21% | -145.71% | -46.51% | -24.6% | 7.64% | -12.41% | -7.1% |
EPS (Basic) | -0.19 | -0.35 | -0.86 | -1.26 | -1.57 | -1.45 | -1.63 | - |
Diluted Shares Outstanding | 49.22M | 49.22M | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M | 107.12M |
Basic Shares Outstanding | 49.22M | 49.22M | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M | 107.12M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
EWTX Balance Sheet
Edgewise Therapeutics, Inc. (EWTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 24.04M | 129.65M | 283.77M | 357M | 327M | 475.48M | 543.38M | 509.79M |
Cash & Short-Term Investments | 23.65M | 129.09M | 280.79M | 351.95M | 318.39M | 470.17M | 530.11M | 499.56M |
Cash Only | 23.65M | 104.92M | 15.57M | 21.99M | 86.1M | 41.67M | 61.15M | 33.21M |
Short-Term Investments | 0 | 24.18M | 265.22M | 329.95M | 232.3M | 428.5M | 468.96M | 466.35M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 8.6M | 5.31M | 13.28M | 10.23M |
Total Non-Current Assets | 498K | 1.49M | 1.46M | 10.1M | 13.04M | 11.33M | 9.22M | 8.73M |
Property, Plant & Equipment | 498K | 516K | 912K | 9.85M | 12.69M | 11.07M | 9.22M | 8.73M |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 975K | 548K | 251K | 348K | 262K | 0 | 0 |
Total Assets | 24.54M▲ 0% | 131.14M▲ 434.4% | 285.23M▲ 117.5% | 367.1M▲ 28.7% | 340.04M▼ 7.4% | 486.82M▲ 43.2% | 552.6M▲ 13.5% | 518.52M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 434.35% | 117.51% | 28.7% | -7.37% | 43.17% | 13.51% | 57.11% |
Total Current Liabilities | 1.13M | 4.34M | 10.52M | 16.59M | 16.77M | 23.86M | 27.37M | 22.54M |
Accounts Payable | 667K | 1.58M | 3.84M | 6.11M | 4.03M | 5.58M | 6.01M | 7.29M |
Days Payables Outstanding | 1.98K | 3.12K | - | - | - | - | 967.43 | 4.3K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 1.01M | 1.02M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 333K | 452K | 2.8M | 4.03M | 5.7M | 10.06M | 20.35M | 14.23M |
Current Ratio | 21.24x | 29.86x | 26.97x | 21.53x | 19.50x | 19.93x | 19.85x | 22.61x |
Quick Ratio | 21.24x | 29.86x | 26.97x | 21.53x | 19.50x | 19.93x | 19.85x | 22.61x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 40.26M | 160.21M | 329K | 3.8M | 4.43M | 3.74M | 2.98M | 2.78M |
Long-Term Debt | 0 | 160.21M | 0 | 0 | 0 | 0 | 2.98M | 2.78M |
Capital Lease Obligations | 0 | 0 | 0 | 3.8M | 4.43M | 3.74M | 0 | 3.37M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 40.26M | 0 | 329K | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 41.39M | 164.56M | 10.85M | 20.39M | 21.2M | 27.6M | 30.35M | 25.32M |
Total Debt | 0 | 160.21M | 0 | 4.41M | 5.41M | 4.74M | 3.99M | 3.79M |
Net Debt | -23.65M | 55.3M | -15.57M | -17.59M | -80.68M | -36.93M | -57.16M | -29.42M |
Debt / Equity | - | - | - | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.15x |
Interest Coverage | - | - | - | -17.83x | - | - | - | - |
Total Equity | -16.85M▲ 0% | -33.42M▼ 98.3% | 274.38M▲ 921.0% | 346.72M▲ 26.4% | 318.83M▼ 8.0% | 459.22M▲ 44.0% | 522.26M▲ 13.7% | 493.2M▲ 0% |
Equity Growth % | - | -98.3% | 921.01% | 26.36% | -8.04% | 44.03% | 13.73% | 58.17% |
Book Value per Share | -0.34 | -0.68 | 5.54 | 6.47 | 5.00 | 4.97 | 5.07 | 4.60 |
Total Shareholders' Equity | -16.85M | -33.42M | 274.38M | 346.72M | 318.83M | 459.22M | 522.26M | 493.2M |
Common Stock | 0 | 0 | 5K | 6K | 7K | 9K | 10K | 10K |
Retained Earnings | -17.02M | -34.15M | -76.96M | -144.6M | -244.76M | -378.58M | -546.37M | -595.38M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -514K | -1.35M | 99K | 420K | 677K | -252K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EWTX Cash Flow Statement
Edgewise Therapeutics, Inc. (EWTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.17M | -14.63M | -33.51M | -52.63M | -91.95M | -109.03M | -143.82M | -148.49M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -59.57% | -128.97% | -57.09% | -74.69% | -18.58% | -31.91% | -107.39% |
Net Income | -9.71M | -17.12M | -42.81M | -67.64M | -100.16M | -133.81M | -167.79M | -176.01M |
Depreciation & Amortization | 123K | 185K | 272K | 538K | 1.73M | 2.29M | 2.27M | 36K |
Stock-Based Compensation | 77K | 354K | 4.4M | 10.92M | 17.56M | 24.71M | 0 | -9.06M |
Deferred Taxes | 0 | 0 | -2.29M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 0 | 2.29M | -543K | -9.52M | -12.54M | 27.09M | -130.95M |
Working Capital Changes | 334K | 1.95M | 4.63M | 4.09M | -1.56M | 10.33M | -5.37M | -306K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 275K | 521K | 2.65M | 47K | -92K | 1.74M | 272K | 992K |
Cash from Investing | -180K | -24.38M | -242.23M | -70.58M | 102.89M | -184.66M | -32.79M | -74.25M |
Capital Expenditures | -180K | -203K | -668K | -5.55M | -5.75M | -1.31M | -256K | -216K |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 241.56K | 65.03K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -241.56K | -65.03K | 0 | 0 | 0 | 3.02M |
Cash from Financing | 24.8M | 120.28M | 186.38M | 129.64M | 53.17M | 249.25M | 196.09M | 206.04M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 24.78M | 120.08M | 186.15M | 129.16M | 52.62M | 239.15M | 196.09M | 204.11M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 22K | 202K | 236K | 474K | 548K | 10.11M | 0 | 1.93M |
Net Change in Cash | 15.45M▲ 0% | 81.26M▲ 426.0% | -89.35M▼ 210.0% | 6.43M▲ 107.2% | 64.1M▲ 897.4% | -44.43M▼ 169.3% | 19.48M▲ 143.8% | -16.71M▲ 0% |
Free Cash Flow | -9.35M▲ 0% | -14.84M▼ 58.7% | -34.17M▼ 130.3% | -58.18M▼ 70.2% | -97.69M▼ 67.9% | -110.34M▼ 12.9% | -143.82M▼ 30.3% | -148.71M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | -58.67% | -130.34% | -70.24% | -67.91% | -12.95% | -30.34% | -24.59% |
FCF per Share | -0.19 | -0.30 | -0.69 | -1.09 | -1.53 | -1.19 | -1.40 | -1.39 |
FCF Conversion (FCF/Net Income) | 0.97x | 0.86x | 0.78x | 0.78x | 0.92x | 0.81x | 0.86x | 0.84x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EWTX Key Ratios
Edgewise Therapeutics, Inc. (EWTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -35.53% | -21.78% | -30.1% | -34.4% | -34.19% | -32.55% |
Return on Invested Capital (ROIC) | - | -23.09% | -18.28% | -30.24% | -36.07% | -32.35% | -30% |
Debt / Equity | - | - | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x |
Interest Coverage | - | - | -17.83x | - | - | - | - |
FCF Conversion | 0.86x | 0.78x | 0.78x | 0.92x | 0.81x | 0.86x | 0.84x |
Related:EWTX Dividend History·EWTX Revenue History·EWTX Price History·EWTX P/E History·EWTX Financial Ratios·EWTX Institutional Holders
EWTX SEC Filings & Documents
Edgewise Therapeutics, Inc. (EWTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
EWTX Frequently Asked Questions
Edgewise Therapeutics, Inc. (EWTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Edgewise Therapeutics, Inc. (EWTX) grew revenue by 0.0% over the past year. Growth has been modest.
Edgewise Therapeutics, Inc. (EWTX) reported a net loss of $176.0M for fiscal year 2025.
Dividend & Returns
Edgewise Therapeutics, Inc. (EWTX) has a return on equity (ROE) of -34.2%. Negative ROE indicates the company is unprofitable.
Edgewise Therapeutics, Inc. (EWTX) had negative free cash flow of $148.7M in fiscal year 2025, likely due to heavy capital investments.